GSK's Oncology Sales Surge 43% as Aggressive Trial Push Reshapes Its Cancer Pipeline

Event Analysis

GlaxoSmithKline (GSK) has emerged as one of the most aggressive oncology players in Big Pharma, with full-year 2025 oncology sales reaching £2.0 billion (+43% at constant exchange rates) and Q1 2025 alone delivering £415 million (+53%), according to GSK's official press releases. The growth is anchored by Jemperli volume expansion following its FDA label broadening and a pipeline that secured 5 FDA approvals in 2025. Seven pivotal trials are now underway, headlined by risvutatug rezetecan (ris-rez), a B7-H3-targeted antibody-drug conjugate (ADC) for second- and third-line extensive-stage small cell lung cancer — a notoriously difficult-to-treat indication. The FDA has also granted ris-rez Orphan Drug Designation, validating the early clinical signals.

What separates this push from prior GSK oncology cycles is the ADC-centric architecture. B7-H3 ADCs are among the most watched mechanisms in oncology right now, and GSK is now running dual tracks: its own ris-rez pivotal trial plus a clinical collaboration with Summit Therapeutics to combine ivonescimab with the GSK B7-H3 ADC. Additional acquisitions — velzatinib/IDRX-42 for GI cancers, partnerships with Hengrui and LTZ Therapeutics — signal a deliberate platform-building strategy rather than opportunistic deal-making. Ten more pivotal trial starts are planned for 2026, which would substantially de-risk the pipeline over the next 18 months.

Context matters, however. GSK's termination of the bintrafusp alfa partnership after a failed lung cancer trial (INTR@PID Lung 037) is a reminder that oncology R&D carries binary outcomes. But the breadth and diversification of the current pipeline — across SCLC, GIST, endometrial, and ADC combinations — reduces single-asset concentration risk relative to earlier cycles. For investors tracking the 2026 Stocks Market Outlook, GSK's oncology transformation represents one of the cleaner fundamental re-rating stories in large-cap healthcare.

What This Means for Traders

GSK stock (NYSE: GSK) is currently trading at $58.25, near its 24-hour low of $58.20, suggesting the market has not yet fully repriced the pipeline acceleration. The flat-to-slightly-negative intraday action (-0.16%) likely reflects broad market caution rather than GSK-specific skepticism. The real volatility catalysts ahead are trial readouts — particularly ris-rez ES-SCLC data and the 2026 pivotal readouts — where binary outcomes can generate sharp single-session moves. Traders should monitor FDA designation updates and partnership announcements as leading indicators.

Across the sector, GSK's ADC momentum creates read-through implications for AstraZeneca PLC (ENHERTU franchise), Pfizer, Inc., and Merck & Co., Inc. as the ADC competitive landscape intensifies. Johnson & Johnson also competes in the oncology ADC space. A sector rotation into high-growth pharma names could lift the FTSE 100 Index modestly given GSK's weighting, though macro factors dominate index-level moves. For stock CFD traders, GSK's core EPS growth of +12% and revenue visibility through Jemperli supports a constructive medium-term bias, with key risk being pipeline failure at any of the seven active pivotal trials.

Trade GSK plc on CoinUnited.io

Trade GSK with up to 800xx leverage → | Create Free Account